金融界12月12日消息，健倍苗苗在2024年上半年度的财报中，其收益总计达到398,953千港元，较2023年同期326,828千港元增长22.1%。其中，品牌药收益130,658千港元，同比增长23.8%；品牌中药收益219,701千港元，增长17.9%；健康保健品收益48,594千港元，增长39.0%。毛利为205,888千港元，增长20.3%，毛利率为51.6%。本公司权益持有人应占溢利95,881千港元，增长53.5%，应占利润率为24.0%。调整后的EBITDA为144,059千港元，增长31.8%，EBITDA率为36.1%。股本回报率为19.0%。期末资产总额为1,409,493千港元，增长1.5%，负债总额为342,796千港元，下降6.5%，权益总额为1,066,697千港元，增长4.4%。以上数据未经审核。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.